Last reviewed · How we verify
(+/-)-Oxamniquine — Competitive Intelligence Brief
marketed
Anthelmintic
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
(+/-)-Oxamniquine (OXAMNIQUINE).
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| (+/-)-Oxamniquine TARGET | OXAMNIQUINE | marketed | Anthelmintic | 1980-01-01 | ||
| Egaten | TRICLABENDAZOLE | Novartis | marketed | Anthelmintic [EPC] | Transthyretin | 2019-01-01 |
| Albenza | ALBENDAZOLE | Impax Labs Inc | marketed | Anthelmintic [EPC] | 1996-01-01 | |
| PRAZIQUANTEL | PRAZIQUANTEL | marketed | Anthelmintic [EPC] | 1982-01-01 | ||
| Vermox | MEBENDAZOLE | marketed | Anthelmintic [EPC] | Vascular endothelial growth factor receptor 2 | 1974-01-01 | |
| Bovizole | THIABENDAZOLE | marketed | Anthelmintic | Cytochrome P450 1A2 | 1967-01-01 | |
| Caricide | DIETHYLCARBAMAZINE | Pfizer | marketed | Anthelmintic | Arachidonate 5-lipoxygenase | 1950-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Anthelmintic class)
- · 2 drugs in this class
- Swiss Tropical & Public Health Institute · 2 drugs in this class
- Merck KGaA, Darmstadt, Germany · 1 drug in this class
- Pfizer · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- (+/-)-Oxamniquine CI watch — RSS
- (+/-)-Oxamniquine CI watch — Atom
- (+/-)-Oxamniquine CI watch — JSON
- (+/-)-Oxamniquine alone — RSS
- Whole Anthelmintic class — RSS
Cite this brief
Drug Landscape (2026). (+/-)-Oxamniquine — Competitive Intelligence Brief. https://druglandscape.com/ci/oxamniquine. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab